Search Results

By Julie R. Gralow, MD, FASCO  / February 10, 2018

Bone-Modifying Agents in Metastatic Breast Cancer: Time to De-escalate Dosing Intervals

AS REVIEWED in this issue of The ASCO Post, ASCO and Cancer Care Ontario (CCO) have issued an updated guideline on the role of bone-modifying agents in metastatic breast cancer.1 The updated guideline supports a change in clinical practice for our patients with breast cancer and bone metastasis....